<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133379</url>
  </required_header>
  <id_info>
    <org_study_id>KOXDHY0001</org_study_id>
    <nct_id>NCT01133379</nct_id>
  </id_info>
  <brief_title>Tooth Sensitivity Relief by Two Mouthrinses</brief_title>
  <official_title>Evaluation of the Efficacy of Two Potassium Oxalate Containing Mouthrinses for Relieving Dentinal Hypersensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Consumer and Personal Products Worldwide</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for people with sensitive teeth and involves going to the dentist for 6 visits
      over 8 weeks. During the first 2 weeks, everyone will just brush their teeth two times a day
      with the fluoride toothpaste provided.

      Then you will be assigned to a mouthwash group if you qualify to continue in the study. Two
      groups will get mouthwash with a certain amount of an experimental ingredient and one group
      will get a mouthwash with no experimental ingredients. You will have an equal chance of being
      assigned to any one of the three groups.

      For the next 6 weeks, you will rinse with your assigned mouthwash after brushing. A dentist
      will look at your mouth, teeth, tongue and gums and check for sensitive teeth. The
      investigators will see if the mouthwash helps to reduce tooth sensitivity during the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, parallel group, single center, controlled clinical trial
      design. Approximately 200 generally healthy adults meeting the necessary inclusion/exclusion
      criteria will be enrolled so that 180 subjects (60 per treatment group) would reasonably be
      expected to complete the study. Subjects will have their oral soft/hard tissues assessed and
      will be evaluated for sensitivity levels at Screening (visit 1), Baseline (visit 2), Week 1,
      Week 2, Week 4 &amp; Week 6. During the first two weeks of the study, subjects will be instructed
      to brush their teeth for one minute in their usual manner, twice daily using the provided
      standard fluoride toothpaste. Subjects will return for the Baseline exam and, upon
      qualification with entry criteria, will be assigned to one of three treatment groups.
      Qualified subjects will be instructed to brush their teeth two times daily for one minute in
      their usual manner using the provided standard fluoride toothpaste. Subjects will be
      instructed to rinse twice daily, after brushing, with the provided mouthrinse for 60 seconds
      using 10 ml or 20 ml (depending on the treatment group), for 6 consecutive weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Tactile Sensitivity Score at Week 6</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Tactile Sensitivity Score at Week 4</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Tactile Sensitivity Score at Week 2</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Tactile Sensitivity Score at Week 1</measure>
    <time_frame>1 Week</time_frame>
    <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Tactile Sensitivity VAS Score at Week 1</measure>
    <time_frame>1 Week</time_frame>
    <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Tactile Sensitivity VAS Score at Week 2</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Tactile Sensitivity VAS Score at Week 4</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Tactile Sensitivity VAS Score at Week 6</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cold Air Stimulus VAS Score at Week 1</measure>
    <time_frame>1 Week</time_frame>
    <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cold Air Stimulus VAS Score at Week 2</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cold Air Stimulus VAS Score at Week 4</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cold Air Stimulus VAS Score at Week 6</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Subjective VAS Score at Week 1</measure>
    <time_frame>1 Week</time_frame>
    <description>At Week 1, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last week when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Subjective VAS Score at Week 2</measure>
    <time_frame>2 Weeks</time_frame>
    <description>At Week 2, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Subjective VAS Score at Week 4</measure>
    <time_frame>4 Weeks</time_frame>
    <description>At Week 4, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Subjective VAS Score at Week 6</measure>
    <time_frame>6 Weeks</time_frame>
    <description>At Week 6, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Dentin Sensitivity</condition>
  <arm_group>
    <arm_group_label>PO-019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PO-020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PO-021</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>12027-019</intervention_name>
    <description>Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.</description>
    <arm_group_label>PO-019</arm_group_label>
    <other_name>1.40% Potassium Oxalate Sensitive Mouthwash without fluoride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>12027-020</intervention_name>
    <description>Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.</description>
    <arm_group_label>PO-020</arm_group_label>
    <other_name>1.40% Potassium Oxalate Sensitive Mouthwash with fluoride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>12027-021</intervention_name>
    <description>Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste</description>
    <arm_group_label>PO-021</arm_group_label>
    <other_name>Vehicle Control Mouthrinse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females at least 18 years of age in good general and oral health without any
             known allergy to commercial dental products or cosmetics.

          -  Evidence of a personally signed and dated informed consent document indicating the
             subject (or legally acceptable representative) has been informed of all pertinent
             aspects of the trial

          -  Willingness to use the assigned products according to instructions, availability for
             appointments, and likelihood of completing the clinical trial.

          -  A minimum of 2 natural premolars, canines, and/or incisors teeth with decay-free
             scorable facial/buccal surfaces which must present cervical abrasion, and/or erosion
             and/or gingival recession.

          -  A minimum of two eligible teeth (premolars, canines and/or incisors) with a Screening
             (-2 weeks Baseline) and Baseline tactile sensitivity score between 10 - 50 grams after
             application of the Yeaple probe and a cold air stimulus VAS score of 30 - 80 mm on a
             100 mm VAS scale will be followed as study teeth during the trial.

          -  No more than two eligible teeth per quadrant each separated by 2 other teeth must be
             selected.Absence of significant oral soft tissue pathology, based on the dentist's
             visual examination and at the discretion of the investigator.

          -  Adequate oral hygiene (i.e. brush teeth daily and exhibit no signs of oral neglect).

          -  Absence of severe marginal gingivitis, moderate/advanced periodontitis (ADA Type III,
             IV) based on a clinical examination and discretion of the Investigator.

          -  Absence of extensive supragingival calculus.

        Exclusion Criteria:

          -  Volunteers who report history or presence of kidney disorders, kidney stones, eating
             disorders, uncontrolled GERD, excessive dietary or environmental exposure to acids, or
             other systemic conditions that are predisposing to dentinal hypersensitivity.

          -  Volunteers with chronic medical debilitating disease associated with constant or
             intermittent episodes of daily pain.

          -  Long-term daily use (â‰¥ 7 consecutive days) of analgesics and any other drugs that at
             the discretion of the Investigator would compromise the response of the
             hypersensitivity assessments.

          -  Volunteers who have been using any home-care bleaching, whitening products or have had
             a professional bleaching treatment within 4 weeks of the Screening visit.

          -  Use of desensitizing agents whether prescribed or over-the-counter within eight weeks
             prior to screening visit (any sensitivity toothpastes such as Crest Sensitivity,
             Sensodyne, Crest Pro-Health, Colgate Sensitivity Relief, any mouthwash and oral care
             products used for the treatment of dentinal hypersensitivity).

          -  Volunteers who during the study will receive dental treatment which may affect their
             dentinal hypersensitivity condition (i.e. oral prophylaxis). Emergency treatment will
             be allowed.

          -  Those requiring antibiotic premedication prior to invasive dental procedures.

          -  Participation in a dental clinical trial involving oral care products within the past
             30 days.

          -  Women who are pregnant, nursing or plan to become pregnant during the course of the
             study.

          -  Teeth that are grossly carious, orthodontically banded, abutment teeth for fixed or
             removable prostheses, crowned teeth, or third molars will not be included in the
             study.

          -  Periodontal surgery and orthodontic treatment within previous 3 months.

          -  Extensive restorative treatment (i.e. extensively restored teeth or teeth with
             restoration(s) extending into the test area) at the discretion of the Investigator.

          -  Dental prophylaxis within 2 weeks prior to Screening visit.

          -  Teeth or periodontium with pathology or defect likely to cause pain.

          -  Teeth with clinical mobility &gt; grade 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Hee</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Consumer and Personal Products Worldwide</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioSci Research America, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2015</results_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Dentin Sensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>12027-021 (Vehicle Control)</title>
          <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
        </group>
        <group group_id="P2">
          <title>12027-019</title>
          <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
        </group>
        <group group_id="P3">
          <title>12027-020</title>
          <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>12027-021 (Vehicle Control)</title>
          <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
        </group>
        <group group_id="B2">
          <title>12027-019</title>
          <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
        </group>
        <group group_id="B3">
          <title>12027-020</title>
          <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="11.36"/>
                    <measurement group_id="B2" value="33.9" spread="10.98"/>
                    <measurement group_id="B3" value="35.8" spread="11.98"/>
                    <measurement group_id="B4" value="35.0" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Tactile Sensitivity Score at Week 6</title>
        <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
        <time_frame>6 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity Score at Week 6</title>
          <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.91" spread="3.342"/>
                    <measurement group_id="O2" value="36.77" spread="3.362"/>
                    <measurement group_id="O3" value="30.16" spread="3.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.811</p_value>
            <p_value_desc>Per statistical analysis plan, if experimental rinse (12027-019) was better than vehicle control at Week 6 (p&lt;0.05), testing for 12027-019 versus vehicle control proceeded to Week 4. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.750</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>8.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <p_value_desc>Per statistical analysis plan, if experimental rinse (12027-020) was better than vehicle control at Week 6 (p&lt;0.05), testing for 12027-020 versus vehicle control proceeded to Week 4. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.750</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Tactile Sensitivity Score at Week 4</title>
        <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
        <time_frame>4 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity Score at Week 4</title>
          <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.58" spread="2.793"/>
                    <measurement group_id="O2" value="31.69" spread="2.809"/>
                    <measurement group_id="O3" value="25.66" spread="2.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.779</p_value>
            <p_value_desc>Per statistical analysis plan, if experimental rinse (12027-019) was better than vehicle control at Week 4 (p&lt;0.05), testing for 12027-019 versus vehicle control proceeded to Week 2. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.969</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.72</ci_lower_limit>
            <ci_upper_limit>8.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <p_value_desc>Per statistical analysis plan, if experimental rinse (12027-020) was better than vehicle control at Week 4 (p&lt;0.05), testing for 12027-020 versus vehicle control proceeded to Week 2. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.969</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.8</ci_lower_limit>
            <ci_upper_limit>2.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Tactile Sensitivity Score at Week 2</title>
        <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
        <time_frame>2 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity Score at Week 2</title>
          <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.27" spread="1.838"/>
                    <measurement group_id="O2" value="22.59" spread="1.849"/>
                    <measurement group_id="O3" value="18.28" spread="1.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <p_value_desc>Per statistical analysis plan, if experimental rinse (12027-019) was better than vehicle control at Week 2 (p&lt;0.05), testing for 12027-019 versus vehicle control proceeded to Week 1. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.613</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>5.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <p_value_desc>Per statistical analysis plan, if experimental rinse (12027-020) was better than vehicle control at Week 2 (p&lt;0.05), testing for 12027-020 versus vehicle control proceeded to Week 1. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.613</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.15</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Tactile Sensitivity Score at Week 1</title>
        <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
        <time_frame>1 Week</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity Score at Week 1</title>
          <description>Tooth sensitivity was measured using a Yeaple probe. The force at which discomfort was felt by the participant was recorded on a scale of 10-80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant, at each visit.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.99" spread="0.944"/>
                    <measurement group_id="O2" value="15.04" spread="0.941"/>
                    <measurement group_id="O3" value="15.03" spread="0.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.477</p_value>
            <p_value_desc>The significance threshold was 0.05. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.336</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.59</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <p_value_desc>The significance threshold was 0.05. Family-wise error rate was controlled at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity (Yeaple probe) score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.336</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.60</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Tactile Sensitivity VAS Score at Week 1</title>
        <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>1 Week</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity VAS Score at Week 1</title>
          <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.09" spread="1.926"/>
                    <measurement group_id="O2" value="39.61" spread="1.927"/>
                    <measurement group_id="O3" value="39.27" spread="1.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.726</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.86</ci_lower_limit>
            <ci_upper_limit>4.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.763</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.723</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.20</ci_lower_limit>
            <ci_upper_limit>4.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Tactile Sensitivity VAS Score at Week 2</title>
        <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>2 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity VAS Score at Week 2</title>
          <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.69" spread="2.010"/>
                    <measurement group_id="O2" value="35.71" spread="2.028"/>
                    <measurement group_id="O3" value="34.79" spread="2.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.488</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.856</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.62</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.854</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.54</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Tactile Sensitivity VAS Score at Week 4</title>
        <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>4 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity VAS Score at Week 4</title>
          <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.06" spread="2.448"/>
                    <measurement group_id="O2" value="29.25" spread="2.469"/>
                    <measurement group_id="O3" value="32.97" spread="2.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.604</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.478</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.68</ci_lower_limit>
            <ci_upper_limit>5.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.583</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.477</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.95</ci_lower_limit>
            <ci_upper_limit>8.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Tactile Sensitivity VAS Score at Week 6</title>
        <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>6 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Tactile Sensitivity VAS Score at Week 6</title>
          <description>Tooth sensitivity was measured using a Visual Analogue Scale (VAS). At each visit, participants rated their perception of the pain/discomfort experienced from the Yeaple probe by marking a single vertical line on a VAS scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The investigator recorded a VAS score of 0 mm for participants who did not experience discomfort at the maximum force of 80 grams. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.50" spread="2.541"/>
                    <measurement group_id="O2" value="24.80" spread="2.563"/>
                    <measurement group_id="O3" value="26.86" spread="2.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.847</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.610</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.83</ci_lower_limit>
            <ci_upper_limit>6.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean tactile sensitivity VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.610</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.77</ci_lower_limit>
            <ci_upper_limit>8.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cold Air Stimulus VAS Score at Week 1</title>
        <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>1 Week</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cold Air Stimulus VAS Score at Week 1</title>
          <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.18" spread="1.894"/>
                    <measurement group_id="O2" value="41.72" spread="1.893"/>
                    <measurement group_id="O3" value="40.30" spread="1.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.360</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.678</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.75</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.679</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.17</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cold Air Stimulus VAS Score at Week 2</title>
        <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>2 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cold Air Stimulus VAS Score at Week 2</title>
          <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.56" spread="2.277"/>
                    <measurement group_id="O2" value="37.95" spread="2.296"/>
                    <measurement group_id="O3" value="36.90" spread="2.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.421</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.235</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.00</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.260</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.235</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cold Air Stimulus VAS Score at Week 4</title>
        <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>4 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cold Air Stimulus VAS Score at Week 4</title>
          <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.92" spread="2.534"/>
                    <measurement group_id="O2" value="31.87" spread="2.556"/>
                    <measurement group_id="O3" value="30.63" spread="2.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.989</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.601</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.16</ci_lower_limit>
            <ci_upper_limit>7.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.721</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.599</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.39</ci_lower_limit>
            <ci_upper_limit>5.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cold Air Stimulus VAS Score at Week 6</title>
        <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
        <time_frame>6 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cold Air Stimulus VAS Score at Week 6</title>
          <description>Tooth sensitivity was measured using a Cold Air Stimulus. When being assessed, participants rated their perception of the pain/discomfort experienced when cold air was directed at the exposed root of each tooth by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm. The score for each participant was calculated by averaging the scores for all study teeth for that participant.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.61" spread="2.597"/>
                    <measurement group_id="O2" value="25.40" spread="2.619"/>
                    <measurement group_id="O3" value="26.28" spread="2.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.743</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.690</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.50</ci_lower_limit>
            <ci_upper_limit>6.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.928</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline mean cold air VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.688</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.61</ci_lower_limit>
            <ci_upper_limit>6.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Subjective VAS Score at Week 1</title>
        <description>At Week 1, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last week when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
        <time_frame>1 Week</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Global Subjective VAS Score at Week 1</title>
          <description>At Week 1, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last week when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.54" spread="1.675"/>
                    <measurement group_id="O2" value="48.51" spread="1.676"/>
                    <measurement group_id="O3" value="47.28" spread="1.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.683</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.369</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.71</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.914</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.371</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.94</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Subjective VAS Score at Week 2</title>
        <description>At Week 2, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
        <time_frame>2 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Global Subjective VAS Score at Week 2</title>
          <description>At Week 2, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.12" spread="2.108"/>
                    <measurement group_id="O2" value="37.93" spread="2.128"/>
                    <measurement group_id="O3" value="38.02" spread="2.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.994</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.997</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Subjective VAS Score at Week 4</title>
        <description>At Week 4, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
        <time_frame>4 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Global Subjective VAS Score at Week 4</title>
          <description>At Week 4, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.92" spread="2.480"/>
                    <measurement group_id="O2" value="33.60" spread="2.503"/>
                    <measurement group_id="O3" value="31.85" spread="2.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.511</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.522</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.27</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.526</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Subjective VAS Score at Week 6</title>
        <description>At Week 6, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
        <time_frame>6 Weeks</time_frame>
        <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>12027-021 (Vehicle Control)</title>
            <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
          </group>
          <group group_id="O2">
            <title>12027-019</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
          </group>
          <group group_id="O3">
            <title>12027-020</title>
            <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Global Subjective VAS Score at Week 6</title>
          <description>At Week 6, participants rated their perception of the pain/discomfort experienced by marking a single vertical line on a Visual Analogue Scale (VAS) scale from 0 to 100 mm, where 0 = No Pain/Discomfort and 100 = Intense Pain/Discomfort. Participants were instructed as follows: &quot;Please rate the intensity of the pain/discomfort you have experienced in the last two weeks when drinking cold/hot beverages and/or foods, eating sweet and sour foods, breathing cold air, brushing your teeth or performing any habits/behaviors that solicit your dentinal hypersensitivity pain/discomfort since you first started using the product.&quot; The dental recorder measured the length of the line from 0 to the participant's line and recorded the VAS score in mm.</description>
          <population>Analysis was based on the Intent-to-Treat Analysis Set, which included all randomized participants who used at least one dose of the study product and had baseline and at least one post-baseline efficacy assessment.</population>
          <units>units on a scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.15" spread="2.593"/>
                    <measurement group_id="O2" value="26.74" spread="2.617"/>
                    <measurement group_id="O3" value="25.31" spread="2.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.684</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was no difference in mean outcome between treatment groups. The alternative hypothesis was a difference in mean outcome between treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.115</p_value>
            <p_value_desc>The significance threshold level was 0.05 (two-sided), with no multiple comparisons adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms included treatment and baseline global subjective VAS score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.687</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.1</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 43 Â± 3 days, + 30 days for serious adverse events.</time_frame>
      <desc>Adverse events were systematically collected at each study visit through Visit 6 (Day 43 Â± 3 days). Serious adverse events were reported through 30 days after product use. Spontaneously reported adverse events collected outside of the regularly scheduled visits were also recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>12027-021 (Vehicle Control)</title>
          <description>Vehicle Control Mouth Rinse (without Potassium Oxalate and without Fluoride) (10 mL)</description>
        </group>
        <group group_id="E2">
          <title>12027-019</title>
          <description>1.40% Potassium Oxalate Sensitive Mouth Rinse without Fluoride (10 mL)</description>
        </group>
        <group group_id="E3">
          <title>12027-020</title>
          <description>1.40% Potassium Oxalate Sensitive Mouth Rinse with Fluoride (20 mL)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal investigator agreed not to publish the study results without prior sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Lynch, DMD, PhD/Study Director</name_or_title>
      <organization>Johnson &amp; Johnson Consumer and Personal Products Worldwide</organization>
      <phone>908-433-6423 USA EST</phone>
      <email>mlynch23@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

